For Research Use Only. Not for Human or Veterinary Use.
Overview
MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S ribosomal RNA gene. In preclinical research it has emerged as a regulator of metabolic homeostasis, insulin sensitivity and exercise physiology, and is often described as an “exercise-mimetic” peptide because it activates the same AMPK-centred stress signalling that exercise does. It is a research compound.
MOTS-c is a peptide encoded inside mitochondrial DNA that, under metabolic stress, moves to the nucleus and influences stress-responsive gene expression. It is studied as an indirect AMPK activator — the master energy sensor — which links it to the metabolic effects usually associated with exercise.
Component
Detail
Primary target
AMPK (indirect), folate–methionine metabolism
AMPK activation
Via altered folate metabolism and AICAR accumulation
Insulin signalling
Studied for enhanced IRS-1/Akt activation and glucose uptake
Upregulation linked to an exercise-like metabolic response
Mitochondrial stress response
Activates the mitochondrial unfolded-protein response (UPRmt)
System
Studied effect
Skeletal muscle
Glucose uptake and fatty-acid oxidation (AMPK, GLUT4)
Adipose tissue
Browning and thermogenesis (FGF21, UCP1)
Liver
Reduced steatosis, improved insulin sensitivity
Aging
Amelioration of age-dependent insulin resistance in models
💊Pharmacology
Parameter
Value
Half-life (t½)
≈ 2–4 h (plasma, estimated)
Bioavailability (SC)
≈ 50–70% (estimated)
Protein binding
Moderate
Metabolism
Proteolytic degradation
Route of administration
SC, intraperitoneal (research)
Elimination
Renal (peptide fragments)
📚Research Evidence
MOTS-c research is at the preclinical stage, mostly in rodent metabolic models. Representative studies and their focus are named below; specific numerical outcomes are not restated here as claims.
Model
Research focus
Reference
High-fat-diet mice
Insulin resistance and glucose tolerance
Lee C, et al. (2015)
Aged mice
Metabolic function and exercise capacity
Reynolds JC, et al. (2020)
Skeletal-muscle cells
AMPK activation and fatty-acid oxidation
MOTS-c preclinical literature
NASH mouse model
Hepatic steatosis and inflammation
MOTS-c preclinical literature
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
Reported direction / finding
Context
Reference
Improved insulin sensitivity and glucose tolerance
For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.
⚗️Dosing & Reconstitution Reference
Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.
Parameter
Reference value
Research dose range (literature)
≈ 5–15 mg per injection, 1–2× weekly, in study protocols
Reconstitution solvent
Bacteriostatic water (0.9% benzyl alcohol)
Final concentration
≈ 5–10 mg/mL
Storage (lyophilized)
−20°C, protected from light
Storage (reconstituted)
2–8°C, up to ~7 days
Do not use
If the solution is cloudy or contains particulates
🛡️Safety Profile
Published research observations, provided for reference only. This material is not for human or veterinary use.
Category
Published observations
Local tolerability
Mild injection-site reactions
Cytotoxicity
No cytotoxicity observed in cell-based assays
Genotoxicity
Negative in standard assays
Glucose
Insulin-sensitizing signal; glucose is monitored in models
Status
For research use only; not for human or veterinary application
📐Physicochemical Properties
Property
Value
Physical state
White to off-white lyophilized powder
Solubility (water)
Freely soluble (> 50 mg/mL)
logP (octanol/water)
≈ −2.1 (hydrophilic)
Isoelectric point (pI)
≈ 12 (basic, arginine-rich)
pH (reconstituted)
5.0–6.0
Stability (lyophilized)
≥ 24 months at −20°C
🏭Synthesis & Manufacturing
MOTS-c is produced by Fmoc solid-phase peptide synthesis. The arginine-rich sequence makes coupling of the basic residues the step that needs the most care.
Step
Detail
Strategy
Fmoc solid-phase peptide synthesis
Resin
Rink amide MBHA resin
Coupling
HBTU / HOBt with DIPEA; double coupling for arginine residues
Cleavage
TFA / TIPS / H₂O (95 : 2.5 : 2.5)
Purification
Preparative RP-HPLC (C18, TFA/ACN gradient)
Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
Critical quality attributes: correct molecular weight and low deletion-peptide content. Arginine-rich sequence with two methionines — confirm absence of deletion peptides and control oxidation.
🔎Analytical Methods
Method
Parameter
Typical result
RP-HPLC (C18, UV 214 nm)
Purity
≥ 98%
HPLC retention
C18, 10–40% B over 25 min
Single main peak
ESI-MS (positive mode)
Identity / mass
consistent with the 16-residue peptide
MALDI-TOF
Mass confirmation
consistent with the 16-residue peptide
Amino-acid analysis
Composition
Consistent with the stated sequence
LC-MS (extracted ion)
Deletion-peptide impurities
Within specification
Karl Fischer
Water content
< 6%
LAL assay
Endotoxin
Within specification
Ion chromatography
Residual TFA
< 500 ppm
Representative RP-HPLC purity method:
Column: C18, 5 µm, 250 × 4.6 mm
Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
Gradient: 10–40% B over 25 min · Flow rate: 1.0 mL/min · Detection: UV 214 nm
Confirmatory LC-MS: ESI positive mode (consistent with the 16-residue peptide). Arginine-rich sequence with two methionines — confirm absence of deletion peptides and control oxidation.
📈Stability Data
Representative stability behaviour under common storage, handling and formulation conditions.
Condition
Duration
Result
Lyophilized, −20°C, dark
≥ 24 months
No significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark
≥ 12 months
Minimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)
3 months
< 5% degradation
Reconstituted, 2–8°C, dark
7–14 days
Minor degradation
Reconstituted, 25°C
24–48 h
Use promptly
Light exposure (ICH Q1B)
1.2 M lux·h
Generally light-stable
Freeze–thaw (−20°C ⇄ 25°C)
3 cycles
Acceptable — aliquot to avoid repeats
Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
Minimise freeze-thaw cycles; aliquot material used across many sessions.
Key factor: Arginine-rich sequence with two methionines — confirm absence of deletion peptides and control oxidation.
📖Selected References
Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 2015.
Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 2020.
Kim KH, et al. Mitochondrial-derived peptides in aging and metabolic regulation (review literature).
✅Quality & Supply
HPLC ≥ 98% purity with a Certificate of Analysis per batch
Identity confirmed by LC-MS
Research samples through to bulk, with worldwide delivery